Recombinant human insulin is the synthetic insulin, developed using recombinant DNA technology by growing insulin proteins within Escherichia coli. Recombinant human insulin has a faster onset of action and lower immunogenicity than other types of insulin such as pork or beef insulin. Human insulin is available primarily in two forms: a short acting (regular) form and an intermediate acting (NPH) form. Moreover, the premixed human insulin is formed by combining two types of insulin, among which one is controls blood sugar level throughout the day, while second type of insulin helps to control blood sugar at meal times. Human recombinant insulin market is gaining traction due to development of biosimilar analogue of insulin, worldwide.
Market Dynamics
Sedentary and unhealthy lifestyle, binge eating, obesity, impaired glucose tolerance, diabetes family history, and increased insulin resistance are some of the risk factors for developing diabetes among the global population. Moreover, increasing number of diabetic population, and growing research and development (R&D) studies in human recombinant insulin to introduce improved version of insulin in the market is expected to boost the growth of human recombinant insulin market in near future. Key manufactures are launching innovative and improved human recombinant insulin in the market to fulfill the increasing demand for insulin. According to the Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS): 2016 report, global insulin market is largely dominated by three pharmaceutical companies: Novo Nordisk A/S, Sanofi S.A. and Eli Lilly and Company. Furthermore, Southeast Asia and Latin America accounts with higher number of smaller human recombinant insulin manufactures, than other regions.
Key features of the study:
• This report provides in-depth analysis of human recombinant insulin in pharmaceutical sector and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global human recombinant insulin market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
• Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Dongbao Enterprise Group Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion and marketing tactics
• The global human recombinant insulin market report caters to various stakeholders in this industry including investors, suppliers, human recombinant insulin manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the human recombinant insulin market.
Detailed Segmentation:
• Global Human Recombinant Insulin Market, By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
• Global Human Recombinant Insulin Market, By Brand:
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
• Global Human Recombinant Insulin Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Human Recombinant Insulin Market, By Region:
o North America
o By Country:
o U.S.
o Canada
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Europe
o By Country:
o Germany
o France
o Italy
o UK
o Spain
o Russia
o Rest of Europe
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Asia Pacific
o By Country:
o China
o India
o Japan
o South Korea
o Australia
o Rest of Asia Pacific
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Middle East
o By Country:
o GCC
o Israel
o Rest of Middle East
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Latin America
o By Country:
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Africa
o By Country:
o South Africa
o Central Africa
o North Africa
o By Product Type:
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
o By Brand
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Company Profiles
o Novo Nordisk A/S *
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments
o Strategies
o Eli Lilly and Company
o Sanofi S.A.
o Julphar Gulf Pharmaceutical Industries
o Biocon Limited
o Bioton S.A.
o Gan & Lee Pharmaceuticals, Ltd.
o Zhuhai United Laboratories Co., Ltd.
o Wanbang Biopharmaceuticals Co., Ltd.
o Dongbao Enterprise Group Co., Ltd.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet By Product Type
o Market Snippet By Brand
o Market Snippet By Distribution Channel
o Market Snippet By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Insulin Market Profile
o Marketing Code Breaches
o Market Trends
o Key Highlights
o Top Global Insulin Manufacturers
o Pipeline Analysis
o Regulatory Scenario
o Reimbursement Scenario
o Epidemiology
o PEST Analysis
4. Global Human Recombinant Insulin Market, By Product Type, 2016 - 2026 (US$ Million)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-O-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Rapid-Acting Human Insulin
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Short-Acting Human Insulin
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Intermediate-Acting Human Insulin
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Long-Acting Human Insulin
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Premixed Human Insulin
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
5. Global Human Recombinant Insulin Market, By Brand, 2016 - 2026 (US$ Million)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-O-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Humalog
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-O-Y Growth Analysis, 2017 - 2026
o Novolog
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Apidra
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Humulin R
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Novolin R
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Humulin N
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Novolin N
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Levemir
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Lantus
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Humalog Mix
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Novolog Mix
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Others
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
6. Global Human Recombinant Insulin Market, By Distribution Channel, 2016 - 2026 (US$ Million)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-O-Y Growth Analysis, 2017 - 2026
o Segment Trends
o Hospital Pharmacies
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Retail Pharmacies
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
o Online Pharmacies
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2016 - 2026, (US$ Million)
7. Global Human Recombinant Insulin Market, By Regions, 2016 - 2026 (US$ Million)
o Market Share Analysis, By Region, 2017 and 2026 (%)
o Y-O-Y Growth Analysis, For Regions, 2017 - 2026
o Market Size and Forecast, By Product Type, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Brand, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o U.S.
o Canada
o Introduction
o North America
o Europe
o Market Size and Forecast, By Product Type, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Brand, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Product Type, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Brand, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o China
o Japan
o India
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Latin America
o Market Size and Forecast, By Product Type, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Brand, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Africa
o Market Size and Forecast, By Product Type, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Brand, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o North Africa
o Central Africa
o South Africa
o Middle East
o Market Size and Forecast, By Product Type, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Brand, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
o Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
o GCC Countries
o Israel
o Rest of Middle East
8. Competitive Landscape
o Company Profiles
o Novo Nordisk A/S
o Company Overview
o Technology Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Eli Lilly and Company
o Company Overview
o Technology Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Sanofi S.A.
o Company Overview
o Technology Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Julphar Gulf Pharmaceutical Industries
o Company Overview
o Technology Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Biocon Limited
o Company Overview
o Technology Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Bioton S.A.
o Company Overview
o Technology Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Gan & Lee Pharmaceuticals, Ltd.
o Company Overview
o Technology Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Zhuhai United Laboratories Co., Ltd.
o Company Overview
o Technology Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Wanbang Biopharmaceuticals Co., Ltd.
o Company Overview
o Technology Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Dongbao Enterprise Group Co., Ltd.
o Analyst Views
9. Section
o References
o Research Methodology
o About Us and Sales Contact
*Browse 35 market data tables and 42 figures on "Human Recombinant Insulin Market - Global forecast to 2026".
Request Discount 
Inquire Before Buy
